A Study About How Bel-sar Treatment Affects Your Daily Life

In Plain English

This study is asking you to share how you're doing while you're in another clinical trial called AU-011-301 (CoMpass) that's testing a new eye cancer treatment called bel-sar. You won't receive any new treatment in this study — instead, you'll answer questions about your life, symptoms, and how you're feeling over the next 2 years. The researchers want to understand the real-world impact of bel-sar beyond just medical measurements: Does it help you see better? Do you have fewer symptoms? Can you do the things you enjoy? Your honest answers help doctors understand whether this treatment actually improves patients' lives, not just what lab tests show. You'll complete surveys online at different time points — starting when you begin treatment and then regularly over 2 years (at weeks 4, 12, 20, 52, 65, 78, 91, and 104). The surveys include custom questions about your experience plus a standard eye cancer quality-of-life questionnaire. This is completely voluntary and separate from your main treatment trial, though you must be enrolled in the CoMpass trial to participate.

What This Trial Does

To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.

How It Works

The AU-011-404 study complements the AU-011-301 clinical trial, and aims to identify the broader impact of bel-sar treatment on subjects' daily lives and overall well-being through the collection of PROs. This noninterventional PRO study will provide valuable insights of treatment impact by capturing real-world perspective on aspects including symptom management, functional status, and overall health-related quality of life (QoL). The sites will direct interested participants to the study via a unique URL. Upon accessing the URL, participants will be asked to complete screening questions to confirm their eligibility and review/sign an informed consent document (ICD). Eligible participants will then be asked to complete custom survey questions and the EORTC QLQ-OPT30 questionnaire for up to 24 months.

Who Can Join

Treatments